Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing ...
10hon MSN
New medicines, access to treatments, infectious disease monitoring, and more are on the table. View on euronews ...
Johnson & Johnson announced the submission of regulatory applications to the U.S. FDA and European Medicines Agency seeking approval of a ...
In 2023/24, the EU launched the Critical Medicines Alliance, while the European Medicines Agency has launched a “solidarity mechanism” for countries to cooperate on shortages. On 18 July 2024 ...
The Canadian healthcare-focused royalty company said Monday that the royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals was acquired for an ...
Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings ...
Patient involvement in health policy is a patchwork across the EU. Putting the lived experience front and centre of policy-making was prioritised at a recent high-level policy event organised by the ...
Astellas to withdraw European marketing authorization application for avacincaptad pegol to treat GA secondary to AMD: Tokyo Tuesday, October 29, 2024, 13:00 Hrs [IST] Astellas Ph ...
The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback